PharmaMar Endures Second Recent Setback With Phase III Ovarian Cancer Failure

Zepsyre did not show a PFS advantage measured against a comparator regimen in platinum-resistant ovarian cancer, but the novel chemotherapy is being tested in nine other cancers.

OvarianCancer_1200x675

PharmaMar SA suffered its second development setback in recent weeks, reporting Jan. 18 that Zepsyre (lurbinectedin) failed a Phase III clinical study in platinum-resistant ovarian cancer. The Spanish biopharma's news followed a negative opinion in Europe in December for its multiple myeloma candidate Aplidin.

PharmaMar is developing Zepsyre, a synthetic alkaloid that binds to the minor groove of DNA and causes cell perturbation theoretically...

More from Clinical Trials

More from R&D